Bluejay Diagnostics Inc (BJDX) FinancialsBJDXBluejay Diagnostics Inc

Evaluating the bottom line, Bluejay Diagnostics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -98.89%, provide a clear picture of how effectively BJDX converts its operational activities into shareholder value.

In the context of the broader market, BJDX competes directly with industry leaders such as ADGM and ICCM. With a market capitalization of $10.50M, it holds a leading position in the sector. When comparing efficiency, BJDX's gross margin of N/A stands against ADGM's N/A and ICCM's 27.89%. Such benchmarking helps identify whether Bluejay Diagnostics Inc is trading at a premium or discount relative to its financial performance.

Bluejay Diagnostics has shown some financial improvement, with Q2 2026 cash and cash equivalents rising to $9.6 million, an 84% increase from the previous year. However, the company continues to report significant net losses, with Q2 2026 showing a loss of $2,324,013.